Cesar A Soutullo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9263371/publications.pdf

Version: 2024-02-01

99 papers

5,594 citations

38 h-index 72 g-index

119 all docs

119 docs citations

119 times ranked 5041 citing authors

#	Article	IF	Citations
1	The management of ADHD in children and adolescents: bringing evidence to the clinic: perspective from the European ADHD Guidelines Group (EAGG). European Child and Adolescent Psychiatry, 2023, 32, 1337-1361.	4.7	46
2	Systematic Review: Medication Effects on Brain Intrinsic Functional Connectivity in Patients With Attention-Deficit/Hyperactivity Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 2021, 60, 222-235.	0.5	26
3	Areas of Interest and Attitudes towards the Pharmacological Treatment of Attention Deficit Hyperactivity Disorder: Thematic and Quantitative Analysis Using Twitter. Journal of Clinical Medicine, 2021, 10, 2668.	2.4	7
4	The World Federation of ADHD International Consensus Statement: 208 Evidence-based conclusions about the disorder. Neuroscience and Biobehavioral Reviews, 2021, 128, 789-818.	6.1	483
5	A commentary on youth onset bipolar disorder. Bipolar Disorders, 2021, 23, 834-837.	1.9	6
6	Resting-State fMRI to Identify the Brain Correlates of Treatment Response to Medications in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder: Lessons From the CUNMET Study. Frontiers in Psychiatry, 2021, 12, 759696.	2.6	4
7	Review of barriers and interventions to promote treatment engagement for pediatric attention deficit hyperactivity disorder care. World Journal of Psychiatry, 2021, 11, 1206-1227.	2.7	14
8	49.2 DIAGNOSTIC STABILITY AND TREATMENT RESPONSE OF BIPOLAR DISORDER IN A LONGITUDINAL FOLLOW-UP OF YOUTH IN SPAIN. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S341.	0.5	0
9	RESTING-STATE FMRI CORRELATES OF CLINICAL RESPONSE TO STIMULANTS IN CHILDREN AND ADOLESCENTS WITH ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2020, 59, S260.	0.5	O
10	Isn't the evidence base for pediatric bipolar disorder already sufficient to inform clinical practice?. Bipolar Disorders, 2020, 22, 664-665.	1.9	5
11	Resting-State fMRI Correlates of Clinical Response to Stimulant Treatments in Children and Adolescents With ADHD. Biological Psychiatry, 2020, 87, S19-S20.	1.3	O
12	ADHD management during the COVID-19 pandemic: guidance from the European ADHD Guidelines Group. The Lancet Child and Adolescent Health, 2020, 4, 412-414.	5.6	163
13	Validation of a Spanish-language version of the ADHD Rating Scale IV in a Spanish sample. NeurologÃa (English Edition), 2019, 34, 563-572.	0.4	4
14	Emerging challenges in pharmacotherapy research on attention-deficit hyperactivity disorderâ€"outcome measures beyond symptom control and clinical trials. Lancet Psychiatry,the, 2019, 6, 528-537.	7.4	26
15	Phenomenology and diagnostic stability of paediatric bipolar disorder in a Spanish sample. Journal of Affective Disorders, 2019, 242, 224-233.	4.1	2
16	Normative ADHD-RS-Preschool Data in a Community Sample in Spain. Journal of Attention Disorders, 2019, 23, 615-623.	2.6	4
17	Validación de la versión en español de la escala de evaluación del trastorno por déficit de atención e hiperactividad (ADHD-RS-IV.es) en una muestra española. NeurologÃa, 2019, 34, 563-572.	0.7	13
18	Clinical and Neuropsychological Predictors of Methylphenidate Response in Children and Adolescents with ADHD: A Naturalistic Follow-up Study in a Spanish Sample. Clinical Practice and Epidemiology in Mental Health, 2019, 15, 160-171.	1.2	8

#	Article	IF	Citations
19	Princesas de cristal Ana López Recalde, Ignacio López-Goñi y Azucena Diez Editorial Almuzara. España; 2019. 168 páginas. Revista De PsiquiatrAa Infanto-Juvenil, 2019, 36, 41-42.	0.3	0
20	Princesas de cristal Ana López Recalde, Ignacio López-Goñi y Azucena Diez Editorial Almuzara. España; 2019. 168 páginas. Revista De PsiquiatrAa Infanto-Juvenil, 2019, 36, 41-42.	0.3	0
21	Practitioner Review: Current best practice in the use of parent training and other behavioural interventions in the treatment of children and adolescents with attention deficit hyperactivity disorder. Journal of Child Psychology and Psychiatry and Allied Disciplines, 2018, 59, 932-947.	5.2	138
22	Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: A systematic review and meta-analysis. Neuroscience and Biobehavioral Reviews, 2018, 84, 63-71.	6.1	113
23	2.42 Pharmacogenetic Predictors of Methylphenidate Response in Children and Adolescents With ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 2018, 57, S172-S173.	0.5	0
24	Risk of poisoning in children and adolescents with ADHD: a systematic review and meta-analysis. Scientific Reports, 2018, 8, 7584.	3.3	22
25	Growth and Puberty in a 2-Year Open-Label Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder. CNS Drugs, 2018, 32, 455-467.	5.9	13
26	Health care and societal costs of the management of children and adolescents with attention-deficit/hyperactivity disorder in Spain: a descriptive analysis. BMC Psychiatry, 2018, 18, 40.	2.6	32
27	Comparative efficacy and tolerability of pharmacological interventions for attention-deficit/hyperactivity disorder in children, adolescents and adults: protocol for a systematic review and network meta-analysis. BMJ Open, 2017, 7, e013967.	1.9	25
28	Systematic review of quality of life and functional outcomes in randomized placebo-controlled studies of medications for attention-deficit/hyperactivity disorder. European Child and Adolescent Psychiatry, 2017, 26, 1283-1307.	4.7	73
29	Risk of unintentional injuries in children and adolescents with ADHD and the impact of ADHD medications: protocol for a systematic review and meta-analysis. BMJ Open, 2017, 7, e018027.	1.9	9
30	Weight, Height, and Body Mass Index in Patients with Attention-Deficit/Hyperactivity Disorder Treated with Methylphenidate. Journal of Child and Adolescent Psychopharmacology, 2017, 27, 723-730.	1.3	31
31	Growth and Sexual Maturation in a 2-year, Open-label Clinical Study of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD. European Psychiatry, 2017, 41, S130-S130.	0.2	0
32	Long-Term Safety and Efficacy of Lisdexamfetamine Dimesylate in Children and Adolescents with ADHD: A Phase IV, 2-Year, Open-Label Study in Europe. CNS Drugs, 2017, 31, 625-638.	5.9	35
33	6.36 ATTENTION-DEFICIT/HYPERACTIVITY DISORDER RATING SCALE: VALIDATION OF A SPANISH VERSION AND A PROPOSAL OF A SHORT-VERSION SCALE. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, S215-S216.	0.5	0
34	Neurofeedback for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 444-455.	0.5	223
35	Time-course of treatment-emergent adverse events in a long-term safety study of lisdexamfetamine dimesylate in children and adolescents with ADHD. European Psychiatry, 2016, 33, S132-S132.	0.2	O
36	The European ADHD Guidelines Group replies:. Journal of the American Academy of Child and Adolescent Psychiatry, 2016, 55, 1092-1093.	0.5	2

#	Article	IF	CITATIONS
37	Cognitive Training for Attention-Deficit/Hyperactivity Disorder: Meta-Analysis of Clinical and Neuropsychological Outcomes From Randomized Controlled Trials. Journal of the American Academy of Child and Adolescent Psychiatry, 2015, 54, 164-174.	0.5	453
38	Differences in maintenance of response upon discontinuation across medication treatments in attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 2015, 25, 1611-1621.	0.7	25
39	Post hoc analyses of the impact of previous medication on the efficacy of lisdexamfetamine dimesylate in the treatment of attention-deficit/hyperactivity disorder in a randomized, controlled trial. Neuropsychiatric Disease and Treatment, 2014, 10, 2039.	2.2	15
40	When do you Prescribe Antidepressants to Depressed Children?. Current Psychiatry Reports, 2013, 15, 366.	4.5	8
41	Health-Related Quality of Life and Functional Outcomes from a Randomized, Controlled Study of Lisdexamfetamine Dimesylate in Children and Adolescents with Attention Deficit Hyperactivity Disorder. CNS Drugs, 2013, 27, 829-840.	5.9	53
42	A Post Hoc Comparison of the Effects of Lisdexamfetamine Dimesylate and Osmotic-Release Oral System Methylphenidate on Symptoms of Attention-Deficit Hyperactivity Disorder in Children and Adolescents. CNS Drugs, 2013, 27, 743-751.	5.9	40
43	European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder. European Neuropsychopharmacology, 2013, 23, 1208-1218.	0.7	101
44	P.7.d.002 Impact of previous ADHD medication on the efficacy of lisdexamfetamine dimesylate in the treatment of ADHD: post hoc analyses. European Neuropsychopharmacology, 2013, 23, S599-S600.	0.7	0
45	Premorbid impairments in early-onset psychosis: Differences between patients with schizophrenia and bipolar disorder. Schizophrenia Research, 2013, 146, 103-110.	2.0	33
46	Evaluating internet information on attention-deficit/hyperactivity disorder (ADHD) treatment: Parent and expert perspectives. Education for Health: Change in Learning and Practice, 2013, 26, 48.	0.3	22
47	Poster #20 ALTERED DEFAULT NETWORK RESTING STATE FUNCTIONAL CONNECTIVITY IN PATIENTS WITH A FIRST EPISODE OF PSYCHOSIS. Schizophrenia Research, 2012, 136, S287-S288.	2.0	0
48	Altered default network resting state functional connectivity in patients with a first episode of psychosis. Schizophrenia Research, 2012, 139, 13-18.	2.0	56
49	El trastorno bipolar, ¿puede diagnosticarse en la edad pediátrica?. Anales De Pediatria Continuada, 2012, 10, 208-216.	0.1	0
50	Lisdexamfetamine Dimesylate. CNS Drugs, 2012, 26, 691-705.	5.9	28
51	Antioxidant defense system and family environment in adolescents with family history of psychosis. BMC Psychiatry, 2012, 12, 200.	2.6	5
52	Differential expression of prostaglandin D2 synthase (PTGDS) in patients with attention deficit–hyperactivity disorder and bipolar disorder. Journal of Affective Disorders, 2012, 138, 479-484.	4.1	20
53	Can positive family factors be protective against the development of psychosis? Psychiatry Research, 2011, 186, 28-33.	3.3	40
54	Structural brain abnormalities in firstâ€episode psychosis: differences between affective psychoses and schizophrenia and relationship to clinical outcome. Bipolar Disorders, 2011, 13, 545-555.	1.9	36

#	Article	IF	CITATIONS
55	Longitudinal changes in brain structure following the first episode of psychosis. Psychiatry Research - Neuroimaging, 2011, 191, 166-173.	1.8	20
56	Pediatric bipolar disorder in a Spanish sample: Results after 2.6 years of follow-up. Journal of Affective Disorders, 2011, 132, 270-274.	4.1	12
57	Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry, 2011, 11, 26.	2.6	94
58	Predominance of Symptoms Over Time in Early-Onset Psychosis. Journal of Clinical Psychiatry, 2010, 71, 327-337.	2.2	26
59	My MotherÊ⅓s Eyes. Journal of the American Academy of Child and Adolescent Psychiatry, 2010, 49, 411-412.	0.5	0
60	Insight correlates in child- and adolescent-onset first episodes of psychosis: results from the CAFEPS study. Psychological Medicine, 2009, 39, 1433-1445.	4.5	43
61	Pediatric bipolar disorder in a Spanish sample: Features before and at the time of diagnosis. Journal of Affective Disorders, 2009, 118, 39-47.	4.1	29
62	Cannabis use in children and adolescents with first episode psychosis: Influence on psychopathology and short-term outcome (CAFEPS study). Schizophrenia Research, 2009, 113, 129-137.	2.0	86
63	Is there a cortical blood flow redistribution pattern related with perseverative error in schizophrenia?. Psychiatria Danubina, 2009, 21, 283-9.	0.4	2
64	Impact of attention-deficit/hyperactivity disorder on the patient and family: results from a European survey. Child and Adolescent Psychiatry and Mental Health, 2008, 2, 31.	2.5	107
65	Antipsychotic Treatment in Child and Adolescent First-Episode Psychosis: A Longitudinal Naturalistic Approach. Journal of Child and Adolescent Psychopharmacology, 2008, 18, 327-336.	1.3	58
66	The child and adolescent first-episode psychosis study (CAFEPS): Design and baseline results. Schizophrenia Research, 2007, 91, 226-237.	2.0	85
67	Psychopathology in children of bipolar parents. Journal of Affective Disorders, 2007, 102, 131-136.	4.1	99
68	Obstetrical complications in children at high risk for bipolar disorder. Journal of Psychiatric Research, 2007, 41, 680-685.	3.1	15
69	Cortical blood flow during rest and Wisconsin Card Sorting Test performance in schizophrenia. Wiener Medizinische Wochenschrift, 2006, 156, 179-184.	1.1	13
70	Adjunctive Lamotrigine Treatment for Adolescents with Bipolar Disorder: Retrospective Report of Five Cases. Journal of Child and Adolescent Psychopharmacology, 2006, 16, 357-364.	1.3	5
71	Bipolar disorder in children and adolescents: international perspective on epidemiology and phenomenology. Bipolar Disorders, 2005, 7, 497-506.	1.9	116
72	Family environment in families with versus families without parental bipolar disorder: a preliminary comparison study. Bipolar Disorders, 2005, 7, 617-622.	1.9	76

#	Article	IF	Citations
73	Worse Quality of Life for Children With Newly Diagnosed Attention-Deficit/Hyperactivity Disorder, Compared With Asthmatic and Healthy Children. Pediatrics, 2005, 116, e364-e369.	2.1	152
74	Psychiatric and Legal Features of 113 Men Convicted of Sexual Offenses. Journal of Clinical Psychiatry, 2004, 65, 293-300.	2,2	155
75	A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. European Child and Adolescent Psychiatry, 2004, 13, 249-57.	4.7	64
76	Quality of Life in 833 outpatients with major depression treated with open-label venlafaxine extended release: An observational 24-week study. International Journal of Psychiatry in Clinical Practice, 2003, 7, 193-197.	2.4	1
77	Academic and Cognitive Abilities in Children of Parents With Bipolar Disorder: A Test of the Nonverbal Learning Disability Model. Journal of Clinical and Experimental Neuropsychology, 2002, 24, 280-285.	1.3	59
78	Obsessive-Compulsive Disorder Secondary to Brain Dysgerminoma in an Adolescent Boy: A Positron Emission Tomography Case Report. Journal of Child and Adolescent Psychopharmacology, 2002, 12, 259-263.	1.3	18
79	Severity of bipolarity in hospitalized manic adolescents with history of stimulant or antidepressant treatment. Journal of Affective Disorders, 2002, 70, 323-327.	4.1	91
80	Reliability of the Washington University in St. Louis Kiddie Schedule for Affective Disorders and Schizophrenia (WASH-U-KSADS) Mania and Rapid Cycling Sections. Journal of the American Academy of Child and Adolescent Psychiatry, 2001, 40, 450-455.	0.5	379
81	Prior stimulant treatment in adolescents with bipolar disorder: association with age at onset. Bipolar Disorders, 2001, 3, 53-57.	1.9	170
82	Divalproex sodium in sex offenders with bipolar disorders and comorbid paraphilias: an open retrospective study. Journal of Affective Disorders, 2001, 64, 249-255.	4.1	16
83	Effects of Race on Psychiatric Diagnosis of Hospitalized Adolescents: A Retrospective Chart Review. Journal of Child and Adolescent Psychopharmacology, 2001, 11, 95-103.	1.3	81
84	First Break of Mania Associated with Topiramate Treatment. Journal of Clinical Psychopharmacology, 2001, 21, 464-466.	1.4	15
85	Six-Month Stability and Outcome of a Prepubertal and Early Adolescent Bipolar Disorder Phenotype. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 165-173.	1.3	76
86	Placebo-Controlled Trial of Sertraline in the Treatment of Binge Eating Disorder. American Journal of Psychiatry, 2000, 157, 1004-1006.	7.2	158
87	Diagnostic Characteristics of 93 Cases of a Prepubertal and Early Adolescent Bipolar Disorder Phenotype by Gender, Puberty and Comorbid Attention Deficit Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2000, 10, 157-164.	1.3	219
88	Racial Differences in Treatment of Adolescents With Bipolar Disorder. American Journal of Psychiatry, 2000, 157, 837-a-838.	7.2	16
89	Olanzapine in the treatment of adolescent acute mania: a report of seven cases. Journal of Affective Disorders, 1999, 53, 279-283.	4.1	67
90	Traumatic brain injury in individuals convicted of sexual offenses with and without bipolar disorder. Psychiatry Research, 1999, 89, 281-286.	3.3	41

#	Article	IF	CITATIONS
91	The psychiatric diagnoses of twenty-two adolescents who have sexually molested other children. Comprehensive Psychiatry, 1999, 40, 85-88.	3.1	57
92	PSYCHOSIS ASSOCIATED WITH PSEUDOEPHEDRINE AND DEXTROMETHORPHAN. Journal of the American Academy of Child and Adolescent Psychiatry, 1999, 38, 1471-1472.	0.5	23
93	Olanzapine in the Treatment of Tardive Dyskinesia. Journal of Clinical Psychopharmacology, 1999, 19, 100-101.	1.4	28
94	Psychiatric Features of 36 Men Convicted of Sexual Offenses. Journal of Clinical Psychiatry, 1999, 60, 414-420.	2.2	111
95	Gabapentin in the Treatment of Adolescent Mania: A Case Report. Journal of Child and Adolescent Psychopharmacology, 1998, 8, 81-85.	1.3	31
96	Cravings and Irresistible Impulses: Similarities Between Addictions and Impulse Control Disorders. Psychiatric Annals, 1998, 28, 592-600.	0.1	14
97	DSM-IV Intermittent Explosive Disorder. Journal of Clinical Psychiatry, 1998, 59, 203-210.	2.2	100
98	Hypomania Associated With Mirtazapine Augmentation of Sertraline. Journal of Clinical Psychiatry, 1998, 59, 320.	2.2	20
99	A pilot trial of adjunctive gabapentin in the treatment of bipolar disorder. Annals of Clinical Psychiatry, 1997, 9, 99-103.	0.6	42